Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Two Directors at Merrimack Pharmaceuticals Inc (MACK) Acquired Almost Half a Million in Stock

June 23, two Board Directors at Merrimack Pharmaceuticals Inc (NASDAQ:MACK), a $741 million market cap biotechnology company, spent a total of $467,787.60 in the company’s stock. Merrimack is engaged in discovering, developing and preparing to commercialize medicines consisting of novel therapeutics paired with companion diagnostics for the treatment of cancer and other serious deceases.

Gary Crocker purchased 36,000 shares of Common Stock for prices ranging from $6.77 to $6.93, inclusive. Following this transaction, in which he spent $246,240.00, the insider owns roughly 2.844 million shares indirectly (by Wife). Another director, Michael Porter, also bought a big amount of Merrimack Pharmaceuticals Inc (NASDAQ:MACK)’s stock. After spending $221,547.60 in 32,390 shares of Common Stock (purchased at prices ranging from $6.80 to $6.87, inclusive), Mr. Porter directly holds 568,255 shares of the company.

Merrimack Pharmaceuticals

Insiders at Merrimack Pharmaceuticals Inc (NASDAQ:MACK) have been particularly active over the past couple of months. Between May 5 and May 20, Mr. Crocker had already purchased 45,300 shares of the company, and Mr. Porter, 45,000 shares. In addition, several other insiders, including the company’s President and CEO, Robert Mulroy, and three other Board Directors, had also acquired the company’s stock in May.

On top of these insiders, several hedge funds seem quite bullish about this company. Brian Ashford-Russell and Tim Woolley’s Polar Capital last declared having upped its stake in the biotech company by 49%, to 3.02 million shares, valued at roughly $3 million by the end of Q1. Ken Griffin’s Citadel Investment Group holds  shares of Merrimack Pharmaceuticals Inc (NASDAQ:MACK) as well. The fund owns bonds worth more than $20 million, 20,800 shares under ‘Put’ options and 19,300 as ‘Call’ options.

Others long on Merrimack are Nathan Fischel (Dafna Capital Management), with 514,853, up 50% over Q1, and Israel Englander (Millennium Management), with 307,886, up 57%.

 

Disclosure: Javier Hasse holds no position in any stocks or funds mentioned.

Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!